Return to homepagePandemic Pact

IMPACT-ICO: Trials of Immuno-Modulatory Particles and Colchicine To Improve COVID-19 Outcomes

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85492

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $676,486.35

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    University of Sydney

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The current coronavirus pandemic is highly contagious and carries a significant risk of death. We propose to test a commonly used inflammatory tablet Colchicine and a novel, biodegradable particle which reduces inflamed cells in the hope that this can improve outcomes. The trial will include 240 people needing oxygen treatment and hospital care for the infection. An expert committee together with consumer representatives will oversee the research.